[go: up one dir, main page]

GT200000020A - Uso de derivados de acidos 4 - biarilbutiricos y 5 - biarilpentanoicos sustituidos para el tratamientodeenfermedades cerebrales. - Google Patents

Uso de derivados de acidos 4 - biarilbutiricos y 5 - biarilpentanoicos sustituidos para el tratamientodeenfermedades cerebrales.

Info

Publication number
GT200000020A
GT200000020A GT200000020A GT200000020A GT200000020A GT 200000020 A GT200000020 A GT 200000020A GT 200000020 A GT200000020 A GT 200000020A GT 200000020 A GT200000020 A GT 200000020A GT 200000020 A GT200000020 A GT 200000020A
Authority
GT
Guatemala
Prior art keywords
treatment
disease
biarilpentanoic
biarilbutiric
refers
Prior art date
Application number
GT200000020A
Other languages
English (en)
Inventor
Volker Hinz
Helmut Haning
Bernd Riedl
Rolf Henning
Andreas Stolle
Jorg Keldenich
Antje Bruck
Joachim Schuhmacher
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of GT200000020A publication Critical patent/GT200000020A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ESTA INVENCION SE REFIERE AL USO DE INHIBIDORES ENZIMATICOS Y, MAS PARTICULARMENTE, A ACIDOS 4 BIARILBUTIRICOS Y 5 BIARILPENTANOICOS CONOCIDOS Y SUS DERIVADOS QUE INHIBEN METALOPROTEASAS DE LA MATRIZ, PARA LA PREVENCION Y TRATAMIENTO DE ENFERMEDADES CEREBRALES. ADEMAS, SE REFIERE AL USO DE COMPUESTOS DE LA SIGUIENTE FORMULA GENERAL: ( T )X A B D E CO2H DONDE ( T )X A REPRESENTA UN RESTO AROMATICO O HETEROAROMATICO SUSTITUIDO O NO SUSTITUIDO, Y B, D & E SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE, ASI COMO EL EJEMPLO QUE SE MUESTRA EN EL DIBUJO. TAMBIEN LA INVENCION SE REFIERE A UN PROCEDIMIENTO PARA TRATAR UN MAMIFERO COMO UN SER HUMANO EN EL TRATAMIENTO Y PREVENCION DE TRASTORNOS NEURODEGENERATIVOS AGUDOS Y CRONICOS QUE INCLUYEN ACCIDENTE CEREBROVASCULAR, LESION CEREBRAL Y DE LA MEDULA ESPINAL TRAUMATICA, ESCLEROSIS LATERAL AMIOTROFICA, ANGIOPATIA AMILOIDE CEREBRAL, LESIONES EN EL SNC EN SIDA, ENFERMEDAD DE ALZHEIMER, ENFERMEDAD DE PARKINSON, ENFERMEDADES DE HUNTINGTON, ENFERMEDADES DE PRIONES, MIASTENIA.
GT200000020A 1999-02-25 2000-02-24 Uso de derivados de acidos 4 - biarilbutiricos y 5 - biarilpentanoicos sustituidos para el tratamientodeenfermedades cerebrales. GT200000020A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99103723A EP1031349A1 (en) 1999-02-25 1999-02-25 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases

Publications (1)

Publication Number Publication Date
GT200000020A true GT200000020A (es) 2001-08-17

Family

ID=8237641

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200000020A GT200000020A (es) 1999-02-25 2000-02-24 Uso de derivados de acidos 4 - biarilbutiricos y 5 - biarilpentanoicos sustituidos para el tratamientodeenfermedades cerebrales.

Country Status (7)

Country Link
EP (2) EP1031349A1 (es)
AR (1) AR036976A1 (es)
AU (1) AU4101900A (es)
CA (1) CA2333955A1 (es)
GT (1) GT200000020A (es)
PE (1) PE20001431A1 (es)
WO (1) WO2000050017A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS276833B6 (en) * 1990-06-18 1992-08-12 Vyzk Ustav Farm Biochem Sp Functional derivatives of 4-(2,4-difluorobiphenylyl)-2-methyl -4- oxobutanoic acid
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
US5886022A (en) * 1995-06-05 1999-03-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors
CO5011061A1 (es) * 1996-05-15 2001-02-28 Bayer Corp Inhibicion de las metaloprotesas de matriz por acidos biariloxobutiricos sustituidos y composiciones farmaceuticas que los contienen
HRP970245B1 (en) * 1996-05-15 2002-06-30 Bayer Ag Biaryl acetilenes as matrix metalloprotease inhibitors
CO5011071A1 (es) * 1996-05-15 2001-02-28 Bayer Corp Inhibicion de las metaloproteinasas de matriz por acidos 2-(w/aroilalquil)-4-biaril-4-oxobutiricos y composiciones farmaceuticas que los contienen
HRP970243B1 (en) * 1996-05-15 2002-06-30 Bayer Ag Inhibition of matrix metalloproteases by substituted phenethyl compounds
AU4159197A (en) * 1996-09-04 1998-03-26 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
MY117687A (en) * 1996-10-31 2004-07-31 Bayer Corp Substituted 4-biphenyl-4-hydroxybutric acid derivatives as matrix metalloprotease inhibitors
PT946166E (pt) * 1996-12-17 2004-06-30 Warner Lambert Co Utilizacao de inibidores das metaloproteinases da matriz para tratar disturbios neurologicos e promover a cicatrizacao de feridas
TR200101970T2 (tr) * 1998-12-30 2002-03-21 Bayer Aktiengesellschaft Solunum yollarì hastalìklarìnìn tedavisinde matriks metaloproteaz inhibit”rleri olarak ikameli 4-biarilbutirik ve 5-biarilpentanoik asit trevlerinin kullanìlmasì

Also Published As

Publication number Publication date
WO2000050017A2 (en) 2000-08-31
AU4101900A (en) 2000-09-14
EP1087761A2 (en) 2001-04-04
CA2333955A1 (en) 2000-08-31
AR036976A1 (es) 2004-10-20
PE20001431A1 (es) 2001-02-14
EP1031349A1 (en) 2000-08-30
WO2000050017A3 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
NO20025517D0 (no) Triazolderivater
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
BR0312232A (pt) Inibidores de caspases e seus usos
ES2188793T3 (es) Agente para el tratamiento de las enfermedades neurodegenerativas.
HUP0003863A3 (en) Alpha-sulfonylamino hidroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders
NO20063276L (no) Anvendelse av rotigotin til behandling eller forhindring av dopaminergt nevrontap
PA8468501A1 (es) Compuestos heterociclicos como inhibidores de enzimas rotamasas
ES2182070T3 (es) Benzofurilderivados y su empleo.
EP1295604A4 (en) PREVENTIVA AND THERAPEUTIA FOR DEMYELINISATION-ASSOCIATED DISEASES
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
BR0111892A (pt) Bis-arilsulfonas
UY28484A1 (es) Compuestos para el tratamiento de trastornos neurodegenerativos
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
ATE325610T1 (de) Xanthinderivative zur behandlung von hirnischämie
AU6896801A (en) Use of vegf and homologues to treat neuron disorders
SV1997000036A (es) Inhibisores de matrices metaloproteasas mediante acidos biaril oxobutiricos sustituidos
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
GT200000020A (es) Uso de derivados de acidos 4 - biarilbutiricos y 5 - biarilpentanoicos sustituidos para el tratamientodeenfermedades cerebrales.
ECSP088280A (es) Compuestos de imidazol para el tratamiento de trastornos neurológicos
BRPI0509559A (pt) compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos
DE69822937D1 (de) Indolmorphinan-derivate und medikamente zur behandlung/mittel zur vorbeugung von cerebralen störungen
ES2156319T3 (es) Derivados de 10,11-dihidro-10-oxo-5h-dibenz/b,f/azepin-5-carboxamida.
PA8642901A1 (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa i
ES2098186A1 (es) Composiciones farmaceuticas a base de aminometilindoles para su aplicacion terapeutica como neuroprotectores en las enfermedades de parkinson y alzheimer.